Nanoconjugate based on polymalic acid for tumor targeting

Julia Y. Ljubimova, Manabu Fujita, Natalya M. Khazenzon, Bong Seop Lee, Sebastian Wachsmann-Hogiu, Daniel L. Farkas, Keith L. Black, Eggehard Holler

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

A new prototype of polymer-derived drug delivery system, the nanoconjugate Polycefin, was tested for its ability to accumulate in tumors based on enhanced permeability and retention (EPR) effect and receptor mediated endocytosis. Polycefin was synthesized for targeted delivery of Morpholino antisense oligonucleotides into certain tumors. It consists of units that are covalently conjugated with poly(β-l-malic acid) (Mw 50,000, Mw/Mn 1.3) highly purified from cultures of myxomycete Physarum polycephalum. The units are active in endosomal uptake, disruption of endosomal membranes, oligonucleotide release in the cytoplasm, and protection against enzymatic degradation in the vascular system. The polymer is biodegradable, non-immunogenic and non-toxic. Polycefin was also coupled with AlexaFluor 680 C2-maleimide dye for in vivo detection. Nude mice received subcutaneous injections of MDA-MB 468 human breast cancer cells into the left posterior mid-dorsum or intracranial injections of human glioma cell line U87MG. Polycefin at concentration of 2.5 mg/kg was injected via the tail vein. In vivo fluorescence tumor imaging was performed at different time points, 0-180 min up to 24 h after the drug injection. The custom-made macro-illumination imaging MISTI system was used to examine the in vivo drug accumulation in animals bearing human breast and brain tumors. In breast tumors the fluorescence signal in large blood vessels and in the tumor increased rapidly until 60 min and remained in the tumor at a level 6 times higher than in non-tumor tissue (180 min) (p < 0.003). In brain tumors drug accumulated selectively in 24 h without any detectable signal in non-tumor areas. The results of live imaging were corroborated histologically by fluorescence microscopic examination of various organs. In addition to tumors, only kidney and liver showed some fluorescent signal.

Original languageEnglish (US)
Pages (from-to)195-203
Number of pages9
JournalChemico-Biological Interactions
Volume171
Issue number2
DOIs
StatePublished - Jan 30 2008

Fingerprint

Nanoconjugates
Tumors
Neoplasms
Breast Neoplasms
Brain Neoplasms
Polymers
Myxomycetes
Fluorescence
Pharmaceutical Preparations
Physarum polycephalum
Vascular Tissue Neoplasms
Morpholinos
Injections
Antisense Oligonucleotides
Optical Imaging
Subcutaneous Injections
Drug Delivery Systems
Endocytosis
Lighting
Nude Mice

Keywords

  • Brain glioma
  • Breast cancer
  • Drug delivery system
  • EPR effect
  • Fluorescence imaging
  • Poly(malic acid)

ASJC Scopus subject areas

  • Toxicology

Cite this

Ljubimova, J. Y., Fujita, M., Khazenzon, N. M., Lee, B. S., Wachsmann-Hogiu, S., Farkas, D. L., ... Holler, E. (2008). Nanoconjugate based on polymalic acid for tumor targeting. Chemico-Biological Interactions, 171(2), 195-203. https://doi.org/10.1016/j.cbi.2007.01.015

Nanoconjugate based on polymalic acid for tumor targeting. / Ljubimova, Julia Y.; Fujita, Manabu; Khazenzon, Natalya M.; Lee, Bong Seop; Wachsmann-Hogiu, Sebastian; Farkas, Daniel L.; Black, Keith L.; Holler, Eggehard.

In: Chemico-Biological Interactions, Vol. 171, No. 2, 30.01.2008, p. 195-203.

Research output: Contribution to journalArticle

Ljubimova, JY, Fujita, M, Khazenzon, NM, Lee, BS, Wachsmann-Hogiu, S, Farkas, DL, Black, KL & Holler, E 2008, 'Nanoconjugate based on polymalic acid for tumor targeting', Chemico-Biological Interactions, vol. 171, no. 2, pp. 195-203. https://doi.org/10.1016/j.cbi.2007.01.015
Ljubimova, Julia Y. ; Fujita, Manabu ; Khazenzon, Natalya M. ; Lee, Bong Seop ; Wachsmann-Hogiu, Sebastian ; Farkas, Daniel L. ; Black, Keith L. ; Holler, Eggehard. / Nanoconjugate based on polymalic acid for tumor targeting. In: Chemico-Biological Interactions. 2008 ; Vol. 171, No. 2. pp. 195-203.
@article{6ab1b47b11d840fc89c74742b8d6ccd8,
title = "Nanoconjugate based on polymalic acid for tumor targeting",
abstract = "A new prototype of polymer-derived drug delivery system, the nanoconjugate Polycefin, was tested for its ability to accumulate in tumors based on enhanced permeability and retention (EPR) effect and receptor mediated endocytosis. Polycefin was synthesized for targeted delivery of Morpholino antisense oligonucleotides into certain tumors. It consists of units that are covalently conjugated with poly(β-l-malic acid) (Mw 50,000, Mw/Mn 1.3) highly purified from cultures of myxomycete Physarum polycephalum. The units are active in endosomal uptake, disruption of endosomal membranes, oligonucleotide release in the cytoplasm, and protection against enzymatic degradation in the vascular system. The polymer is biodegradable, non-immunogenic and non-toxic. Polycefin was also coupled with AlexaFluor 680 C2-maleimide dye for in vivo detection. Nude mice received subcutaneous injections of MDA-MB 468 human breast cancer cells into the left posterior mid-dorsum or intracranial injections of human glioma cell line U87MG. Polycefin at concentration of 2.5 mg/kg was injected via the tail vein. In vivo fluorescence tumor imaging was performed at different time points, 0-180 min up to 24 h after the drug injection. The custom-made macro-illumination imaging MISTI system was used to examine the in vivo drug accumulation in animals bearing human breast and brain tumors. In breast tumors the fluorescence signal in large blood vessels and in the tumor increased rapidly until 60 min and remained in the tumor at a level 6 times higher than in non-tumor tissue (180 min) (p < 0.003). In brain tumors drug accumulated selectively in 24 h without any detectable signal in non-tumor areas. The results of live imaging were corroborated histologically by fluorescence microscopic examination of various organs. In addition to tumors, only kidney and liver showed some fluorescent signal.",
keywords = "Brain glioma, Breast cancer, Drug delivery system, EPR effect, Fluorescence imaging, Poly(malic acid)",
author = "Ljubimova, {Julia Y.} and Manabu Fujita and Khazenzon, {Natalya M.} and Lee, {Bong Seop} and Sebastian Wachsmann-Hogiu and Farkas, {Daniel L.} and Black, {Keith L.} and Eggehard Holler",
year = "2008",
month = "1",
day = "30",
doi = "10.1016/j.cbi.2007.01.015",
language = "English (US)",
volume = "171",
pages = "195--203",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Nanoconjugate based on polymalic acid for tumor targeting

AU - Ljubimova, Julia Y.

AU - Fujita, Manabu

AU - Khazenzon, Natalya M.

AU - Lee, Bong Seop

AU - Wachsmann-Hogiu, Sebastian

AU - Farkas, Daniel L.

AU - Black, Keith L.

AU - Holler, Eggehard

PY - 2008/1/30

Y1 - 2008/1/30

N2 - A new prototype of polymer-derived drug delivery system, the nanoconjugate Polycefin, was tested for its ability to accumulate in tumors based on enhanced permeability and retention (EPR) effect and receptor mediated endocytosis. Polycefin was synthesized for targeted delivery of Morpholino antisense oligonucleotides into certain tumors. It consists of units that are covalently conjugated with poly(β-l-malic acid) (Mw 50,000, Mw/Mn 1.3) highly purified from cultures of myxomycete Physarum polycephalum. The units are active in endosomal uptake, disruption of endosomal membranes, oligonucleotide release in the cytoplasm, and protection against enzymatic degradation in the vascular system. The polymer is biodegradable, non-immunogenic and non-toxic. Polycefin was also coupled with AlexaFluor 680 C2-maleimide dye for in vivo detection. Nude mice received subcutaneous injections of MDA-MB 468 human breast cancer cells into the left posterior mid-dorsum or intracranial injections of human glioma cell line U87MG. Polycefin at concentration of 2.5 mg/kg was injected via the tail vein. In vivo fluorescence tumor imaging was performed at different time points, 0-180 min up to 24 h after the drug injection. The custom-made macro-illumination imaging MISTI system was used to examine the in vivo drug accumulation in animals bearing human breast and brain tumors. In breast tumors the fluorescence signal in large blood vessels and in the tumor increased rapidly until 60 min and remained in the tumor at a level 6 times higher than in non-tumor tissue (180 min) (p < 0.003). In brain tumors drug accumulated selectively in 24 h without any detectable signal in non-tumor areas. The results of live imaging were corroborated histologically by fluorescence microscopic examination of various organs. In addition to tumors, only kidney and liver showed some fluorescent signal.

AB - A new prototype of polymer-derived drug delivery system, the nanoconjugate Polycefin, was tested for its ability to accumulate in tumors based on enhanced permeability and retention (EPR) effect and receptor mediated endocytosis. Polycefin was synthesized for targeted delivery of Morpholino antisense oligonucleotides into certain tumors. It consists of units that are covalently conjugated with poly(β-l-malic acid) (Mw 50,000, Mw/Mn 1.3) highly purified from cultures of myxomycete Physarum polycephalum. The units are active in endosomal uptake, disruption of endosomal membranes, oligonucleotide release in the cytoplasm, and protection against enzymatic degradation in the vascular system. The polymer is biodegradable, non-immunogenic and non-toxic. Polycefin was also coupled with AlexaFluor 680 C2-maleimide dye for in vivo detection. Nude mice received subcutaneous injections of MDA-MB 468 human breast cancer cells into the left posterior mid-dorsum or intracranial injections of human glioma cell line U87MG. Polycefin at concentration of 2.5 mg/kg was injected via the tail vein. In vivo fluorescence tumor imaging was performed at different time points, 0-180 min up to 24 h after the drug injection. The custom-made macro-illumination imaging MISTI system was used to examine the in vivo drug accumulation in animals bearing human breast and brain tumors. In breast tumors the fluorescence signal in large blood vessels and in the tumor increased rapidly until 60 min and remained in the tumor at a level 6 times higher than in non-tumor tissue (180 min) (p < 0.003). In brain tumors drug accumulated selectively in 24 h without any detectable signal in non-tumor areas. The results of live imaging were corroborated histologically by fluorescence microscopic examination of various organs. In addition to tumors, only kidney and liver showed some fluorescent signal.

KW - Brain glioma

KW - Breast cancer

KW - Drug delivery system

KW - EPR effect

KW - Fluorescence imaging

KW - Poly(malic acid)

UR - http://www.scopus.com/inward/record.url?scp=38349148359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349148359&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2007.01.015

DO - 10.1016/j.cbi.2007.01.015

M3 - Article

VL - 171

SP - 195

EP - 203

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 2

ER -